02/01/23 6:30 AMNasdaq : BCDA low floatBioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for PatientsBioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repairRHEA-AIvery positive
12/22/22 7:00 AMNasdaq : BCDA low floatBioCardia Letter to ShareholdersBioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders, BioCardia is nowRHEA-AIneutral
12/15/22 7:00 AMNasdaq : BCDA low floatBioCardia Announces $3.6 Million Private Placement of Common StockBioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and RegistrationRHEA-AIneutral
12/06/22 7:00 AMNasdaq : BCDA fda approvallow floatBioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart FailureBioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration approval of its Investigational New Drug application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive allogeneic human...RHEA-AIneutral
11/09/22 4:05 PMNasdaq : BCDA earningslow floatBioCardia Reports Third Quarter 2022 Business Highlights and Financial ResultsBioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report onRHEA-AIpositive
11/02/22 5:31 PMNasdaq : BCDA conferencesearningslow floatBioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022BioCardia ®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months endedRHEA-AIneutral
10/03/22 7:00 AMNasdaq : BCDA low floatBioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual MeetingBioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonaryRHEA-AIneutral
09/14/22 7:00 AMNasdaq : BCDA low floatCardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual MeetingBioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that new data from itsRHEA-AIneutral
09/09/22 7:00 AMNasdaq : BCDA low floatBioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held on September 12-14, 2022. The in-person venue for theRHEA-AIneutral
09/08/22 7:00 AMNasdaq : BCDA conferenceslow floatBioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines ConferenceBioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald’s Cell and Genetic Medicines Conference. The conference is being held in person on September 15, 2022, at the LotteRHEA-AIneutral